Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KH9702
- Development stage
- Unknown
- Lead developer
- Chengdu Kanghong Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
KH9702 is a small molecule, highly selective inhibitor of the voltage-gated sodium channel Nav1.8 (SCN10A), currently under development by Chengdu Kanghong Biotech for the treatment of acute pain. Nav1.8 is a sodium channel subtype primarily expressed in peripheral nociceptive neurons, where it plays a critical role in the initiation and transmission of pain signals. By selectively blocking this channel, KH9702 aims to provide potent analgesia while avoiding the central nervous system side effects and addiction potential associated with opioids, as well as the systemic risks linked to nonsteroidal anti-inflammatory drugs (NSAIDs). The drug is formulated as an oral tablet and has entered early-stage clinical evaluation in China.
Beyond the preview
Go deeper on KH9702.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KH9702.